Hyperion DeFi, Inc.
HYPD Healthcare Biotechnology
Hyperion DeFi, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $813,500.00, up 1,319.7% from fiscal 2024. In the quarter to June 2026, revenue grew 2,333.3%, EPS grew 140.4%, free cash flow grew 86.8% and total debt rose 12.3%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow HYPD
Hyperion DeFi, Inc. (HYPD) P/E ratio
Hyperion DeFi, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 11 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IBIO iBio, Inc. compare | n/m |
| ACET Adicet Bio, Inc. compare | n/m |
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| LONA LeonaBio, Inc. compare | n/m |
| ELTX Elicio Therapeutics, Inc. compare | n/m |
| HOWL Werewolf Therapeutics, Inc. compare | n/m |
| MREO Mereo BioPharma Group plc - Sponsored ADR compare | n/m |
| HYPD Hyperion DeFi, Inc. | n/m |
| CRBU Caribou Biosciences, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)